MGNX - MacroGenics

-

$undefined

N/A

(N/A)

MacroGenics NasdaqGS:MGNX MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Location: 9704 Medical Center Drive, Rockville, MD, 20850, United States | Website: https://www.macrogenics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-28.35M

Cash

154.1M

Avg Qtr Burn

-17.41M

Short % of Float

11.79%

Insider Ownership

3.01%

Institutional Own.

89.59%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer

Approved

Quarterly sales

Retifanlimab (anti-PD-1 mAb) Details
Solid tumor/s, Non-small cell lung carcinoma, Anal cancer, Lung cancer, Cancer

PDUFA

Approval decision

Phase 2

Data readout

Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Phase 2

Data readout

Vobramitamab duocarmazine (vobra duo) (MGC018) Details
Castration-resistant prostate cancer, Cancer, Solid tumor/s

Phase 2

Update

Lorigerlimab monotherapy Details
Cancer, Platinum-resistant ovarian cancer

Phase 2

Initiation

MGC026 Details
Cancer, Solid tumor/s

Phase 1

Data readout

MGD024 Details
Acute myeloid leukemia, Myelodysplastic syndrome

Phase 1

Data readout

Vobramitamab duocarmazine (vobra duo) w/lorigerlimab Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Melanoma, Castration-resistant prostate cancer

Failed

Discontinued

Failed

Discontinued

Flotetuzumab (bispecific CD123 × CD3 DART molecule) Details
Cancer, Multiple myeloma, Acute myeloid leukemia

Failed

Discontinued

Enoblituzumab (anti-B7-H3) Details
Head and neck squamous cell carcinoma, Cancer

Failed

Discontinued